HealthQuill Biotechnology
Citius Pharmaceuticals, Inc., a US-based biotechnology company, got a green light from the country’s drug regulator for its immunotherapy treatment for a rare form of blood cancer that affects the skin.
Drugs Health Pharma

Citius’s blood cancer drug gets US regulatory body’s clearance 

Citius Pharmaceuticals, Inc., a US-based biotechnology company, got a green light from the country’s drug regulator for its immunotherapy treatment for a rare.

Read More
An oral investigational drug jointly developed by Biogen Inc., and Sage Therapeutics Inc., failed to stop essential tremors in patients, forcing the companies to halt the trial.
Drugs Health Pharma

Biogen, Sage halt tremor trial after ‘disappointing’ oral drug results

An oral investigational drug jointly developed by Biogen Inc., and Sage Therapeutics Inc., failed to stop essential tremors in patients, forcing the companies.

Read More
Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.
Drugs Health Pharma

Roche to pay $42 million to Ascidian to make RNA exon editing drugs

Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.

Read More
Researchers have reworked DNA and proteins, the essential building blocks of life, to create cells that look and act like cells from the body — a discovery that may aid regenerative medicine, drug delivery systems, and diagnostic tools.
Drugs Health Pharma

UNC researchers close gap between synthetic and living human cells

HQ Team April 26, 2024: Researchers have reworked DNA and proteins, the essential building blocks of life, to create cells that look and.

Read More
Merck & Co., will acquire Harpoon Therapeutics, Inc., for $680 million to expand its cancer drug portfolio — a transaction expected to close by the middle of this year.
Drugs Health Pharma

Merck to buy Harpoon for $680 million to step up cancer portfolio

HQ Team January 8, 2024: Merck & Co., will acquire Harpoon Therapeutics, Inc., for $680 million to expand its cancer drug portfolio —.

Read More
Swiss biotechnology company, Basilea Pharmaceutica’s last stage trials of ceftobiprole to treat bacterial bloodstream infections have shown favourable outcomes, according to a statement.
Drugs Health Pharma

Swiss firm Basilea reports positive results in late-stage Staph trials

HQ Team September 28, 2023: Swiss biotechnology company, Basilea Pharmaceutica’s last stage trials of ceftobiprole to treat bacterial bloodstream infections have shown favourable.

Read More